Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show? - 2Pick Your Number one sort of blossom
- 3Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- 4The Most Astonishing Arising Advancements to Watch
- 5NASA launches science balloon in Antarctica | Space photo of the day for Dec. 22, 2025
- Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.'
- Figure out How to Put resources into Lab Precious stones
- Europe could get 42 more days of summer by the year 2100 due to climate change
- Focus on Yourself: Wellbeing and Taking care of oneself Practices
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- New method spots signs of Earth's primordial life in ancient rocks
- Best Streaming Gadget for Your Home Theater
- Flu illness count nears 5 million, with New York City among the hardest hit
- As world leaders enter climate talks, people in poverty have the most at stake
